### Facility and Process Flexibilities – The Benefits of Modular and Prefabricated Cleanroom Structures in a New Era of Therapies






Maik W. Jornitz CEO G-CON Manufacturing Inc

### Agenda

- New Needs Voiced
- The Facility Options of the Past
- The Facility Options of Now
- Rethinking the Options
- Some Examples
- I Like, I Like, I Wonder...
- Conclusion







## **Facility Needs Voiced**

- Delivery time and budget proposals for facilities and cleanrooms require to be robust
- Man hours and other hidden costs need to shift off-site
- Facilities require to be rapidly deployable (6-12 months)
- Scaling of the facility should not disrupt existing processes
- Infrastructure require to be repurposable, instead of being sunk asset
- Cloning of facilities and infrastructures help design abbreviation, personnel training and regulatory familiarity










### **The Options - Past**

- High CAPEX/higher OPEX
- Extensive time-to-run (>3 years)
- Product dedicated
- Inflexible, often difficult to expand
- Extensive design phases
- Difficult containment, high complexity
- Complex maintenance & aging
- Difficult tech transfer & cloning



Latest Experimental Alzheimer's Drug Fails Testing (WSJ 03/21)





## **The Options - Now**

- Potentially predesigned, like KuBio or iCON
- Time-to-run 12 18 months
- Delayed investment due to faster build
- Flexible and scalable\*
- Predefined design phases
- VHP sanitizable containment\*
- Clonable
- Predictable cost budgets and delivery times









# **Rethinking – Facility (Infrastructure) Concepts**

#### **Standardization**

8 different configurations mass produced

Benefits:

- deliverable within weeks
- much lower cost
- no design timelines & costs
- prequalification packages






#### **Predesigned Platforms**

Catalogue of different application turnkey platforms

Benefits:

- greatly abbreviated design efforts
- much faster delivery
- reduced costs due to repeat built
- cloning possibilities







### **New Solution - Examples**



Pediatric gene therapy -14 units -8 months Phase 2 -10 units -5.5 months



Aseptic filling site – 4 units – 10 months



Bioprocess site – 10 units – 10 months

**Other Projects:** 

Bioprocess – 8 units – 8 months

CAR T – 1 unit – 3.5 months

CAR T – 3 units – 7 months

Gene therapy – 8 units – 6 months




### "I Like, I Like, I Wonder..."






- ✓ We can lease cars
- ✓ We get cars delivered in weeks
- $\checkmark$  We can configure cars online
- $\checkmark\,$  We can check them in showrooms



## Conclusion

- In a new era of therapies, the "old and traditional" does not fit
- Single-use process flexibilities required to be transformed to facilities
- Rapid deployment of facilities is necessary and possible off-site mass production could accelerate delivery time
- Segregation is essential to scale w/o interruption and contain when needed
- Most importantly; to develop and implement new technologies collaboration of all (industry, regulators and suppliers) is needed





"Alone we can do so little:



### Thank you !

A pessimist sees the difficulty in every opportunity; an optimist sees the opportunity in every difficulty.

Sir Winston Churchill



